Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs SNY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Captures Overall Composite Edge (41.5 SELL vs 31.7 SELL), While SNY Leads 3–2 on Growth & Valuation Pillars

NVS Overall Winner 6-Pillar Tally: NVS 2 – 3 SNY (1 Tie) Matrix Metrics: NVS 6 – 3 SNY

As of Nov 16, 2026, Novartis AG (NVS) captures the overall head-to-head institutional edge over Sanofi (SNY) on higher Unified Composite conviction (41.5/100 SELL vs. 31.7/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality, Balance Sheet & Cash Flow), while SNY wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus SNY at $48.61 (8.9x Forward P/E, 22.3% operating margin).

  • Growth vs. Quality Trade-Off: NVS earns the overall head-to-head edge with a stronger Unified Composite Score (41.5/100 SELL vs. SNY 31.7/100 SELL) and 0.31β · 27% Vol risk profile, whereas SNY leads top-line expansion (+15.7% YoY revenue growth, 1.76x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although NVS compares more favorably head-to-head, both NVS (41.5/100 SELL) and SNY (31.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs SNY
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17
SNY NASDAQ
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Pharmaceutical Preparations
$48.61
+0.5% 1D
Market Cap $116.0B
TTM Revenue $30.0B
Forward P/E 8.9x
Beta / 30D Vol 0.21β · 27% Vol
Unified Composite Score
31.7 / 100 SELL
Tech 50.0 Fund 28.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 77
RSI-14: 77.5 · SMA20: $45.10 · SMA50: $42.77

6-Pillar Scorecard Institutional Category Breakdown (NVS 2 – 3 SNY)

Columns: Metric · NVS · SNY
1. Valuation Multiples SNY
Forward P/E 16.2x 8.9x
Trailing P/E 30.6x 24.1x
PEG Ratio 3.81x 1.76x
EV / Revenue 7.5x 3.9x
2. Growth & Scale SNY
Revenue Growth (YoY) +4.7% +15.7%
Earnings Growth (YoY) -68.8% +9.4%
TTM Revenue (USD) $40.5B $30.0B
Market Cap $302.9B $116.0B
3. Profitability & Quality NVS
Gross Margin 75.2% 74.3%
Operating Margin 34.0% 22.3%
Net Profit Margin 17.5% 8.2%
Return on Equity (ROE) 24.3% 5.7%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $8.70B EBITDA
Cash Flow Margin 42.0% EBITDA Mgn 29.0% EBITDA Mgn
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $34.11 Book/Sh · 5.7% ROE
Dividend Yield 2.96% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 16.9% (6th %ile) 22.0% (43rd %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNY
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 52.0% of Rev ($15.6B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (6) vs SNY (3)
Institutional Metric NVS SNY Criterion Row Edge
Market Capitalization
Scale
$302.9B $116.0B Larger Scale NVS
Trailing P/E Ratio
Valuation
30.6x 24.1x Lower Multiple SNY
Forward P/E Ratio
Valuation
16.2x 8.9x Lower Multiple SNY
Revenue Growth (YoY)
Growth
+4.7% +15.7% Higher Growth SNY
Operating Margin (TTM)
Profitability
34.0% 22.3% Higher Margin NVS
Net Profit Margin
Profitability
17.5% 8.2% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% 5.7% Higher ROE NVS
52-Week Range Position
Momentum
81% ($123–$170) 70% ($39–$53) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol 0.21β · 27% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 31.7 / 100 (SELL) Higher Composite NVS
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $30.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 74.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 7.5x EV/Rev 1.76x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $8.70B EBITDA ($34.11 Book/Sh · 5.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNY +12.42 pp
NVS: +7.28% · SNY: +19.7%
3M Horizon SNY +3.53 pp
NVS: +4.56% · SNY: +8.09%
6M Horizon SNY +3.3 pp
NVS: +8.34% · SNY: +11.64%
1Y Horizon NVS +29.63 pp
NVS: +22.5% · SNY: -7.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs SNY. Trailing 12-month operating profitability (NVS 34.0% vs SNY 22.3%) and valuation multiples (NVS 16.2x vs SNY 8.9x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x
SNY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$30.0B
Gross Margin74.3%
Op. Margin22.3%
ROE / Fwd P/E5.7% · 8.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.0%
IV Percentile 43rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
SNY Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $116.0B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment 52.0% of Rev ($15.6B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs SNY Key Questions & Quantitative Answers

As of Nov 16, 2026, Novartis AG (NVS) captures the overall head-to-head institutional edge over Sanofi (SNY) on higher Unified Composite conviction (41.5/100 SELL vs. 31.7/100 SELL) after splitting the core matrix 6–3 (led by Profitability & Quality, Balance Sheet & Cash Flow), while SNY wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus SNY at $48.61 (8.9x Forward P/E, 22.3% operating margin). Growth vs. Quality Trade-Off: NVS earns the overall head-to-head edge with a stronger Unified Composite Score (41.5/100 SELL vs. SNY 31.7/100 SELL) and 0.31β · 27% Vol risk profile, whereas SNY leads top-line expansion (+15.7% YoY revenue growth, 1.76x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although NVS compares more favorably head-to-head, both NVS (41.5/100 SELL) and SNY (31.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SNY leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with SNY at +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.0B TTM revenue (74.3% gross margin, 22.3% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $30.0B for SNY. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 52.0% of Rev ($15.6B) (0 disclosures) for SNY.

SNY screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas SNY trades at 8.9x Forward P/E, 24.1x Trailing P/E, 1.76x PEG, and 3.9x EV/Revenue (29.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus SNY (5.7% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.21β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.